cisplatin | paclitaxel | doxorubicin | topotecan | |
---|---|---|---|---|
W1 | 151 (96–216) |
3,37 (3,18–3,62) |
13,6 (9,1–18,0) |
2,03 (1,94–2,11) |
A2780 | 439 (283–565) |
3,43 (1,91–4,73) |
19,79 (12,52–24,44) |
3,13 (1,48–4,71) |
SKOV-3 | 890 (595–1222) |
0,784 (0,73–0,84) |
17,76 (13,7–22,84) |
51,9 (40,34–60,71) |
OVCAR-3 | 2613 (2125–2884) |
458 (372–594) |
354 (203–571) |
398 (283–505) |
PEA1 | 2737 (2031–3763) |
5,66 (3,25–9,07) |
81 (72–90) |
29 (19,2–46,9) |
PEA2 | 2469 (2426–2557) |
6,88 (4,31–8,38) |
173 (148–195) |
132 (79–188) |
PEO23 | 2171 (1839–2438) |
1404 (1000–1600) |
275 (198–375) |
498 (300–750) |
W1 | tumor tissue, ovarian serous adenocarcinoma | No | N/A |
A2780 | tumour tissue, ovarian endometrioid adenocarcinoma | No | N/A |
SKOV-3 | ascites, ovarian serous adenocarcinoma | ThioTEPA | ineffective |
OVCAR-3 | ascites, ovarian serous adenocarcinoma, high grade | cyclophosphamide, DOX, CIS | ineffective |
PEA1 | pleural effusion, serous adenocarcinoma, high grade | No | N/A |
PEA2 | ascites, serous adenocarcinoma, high grade | CIS, Prednimustine | ineffective |
PEA O23 | ascites, serous adenocarcinoma, low grade | CIS, chlorambucil | ineffective |
MCTP1 | F | AGAACCTCAACCCTGTGTGG | 00000312216 | 123 bp |
R | AGGCTGAGCCCATAAAGTCA | |||
IFIH1 | F | GGGGCATGGAGAATAACTCA | 00000263642 | 132 bp |
R | TGCCCATGTTGCTGTTATGT | |||
SAMD4 | F | CCAAAGGTGCAAGACACAAA | 00000251091 | 146 bp |
R | CGGAGTCAGGATCATCTGGT | |||
HERC5 | F | CTTCCTGCATGTGGTTTCCT | 00000264350 | 128 bp |
R | AAACAGTGCCAGTGGGAAAG | |||
SEMA3A | F | TGTTGGAGCAAAGGATCACA | 00000265362 | 109 bp |
R | AGCCCACTTGCATTCATCTC | |||
GAPDH | F | GAAGGTGAAGGTCGGAGTCA | 00000229239 | 199 bp |
R | GACAAGCTTCCCGTTCTCAG | |||
β-actin | F | TCTGGCACCACACCTTCTAC | 00000331789 | 169 bp |
R | GATAGCACAGCCTGGATAGC | |||
HPRT1 | F | CTGAGGATTTGGAAAGGGTG | 00000298556 | 156 bp |
R | AATCCAGCAGGTCAGCAAAG | |||
B2M | F | CGCTACTCTCTCTTTCTGGC | 00000558401 | 133 bp |
R | ATGTCGGATGGATGAAACCC |